{"id":221216,"date":"2025-08-30T19:12:06","date_gmt":"2025-08-31T00:12:06","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2025\/08\/transferrin-receptor-targeted-anti-amyloid-antibody-enhances-brain-delivery-and-mitigates-aria"},"modified":"2025-08-30T19:12:06","modified_gmt":"2025-08-31T00:12:06","slug":"transferrin-receptor-targeted-anti-amyloid-antibody-enhances-brain-delivery-and-mitigates-aria","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2025\/08\/transferrin-receptor-targeted-anti-amyloid-antibody-enhances-brain-delivery-and-mitigates-aria","title":{"rendered":"Transferrin receptor\u2013targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/transferrin-receptor-targeted-anti-amyloid-antibody-enhances-brain-delivery-and-mitigates-aria2.jpg\"><\/a><\/p>\n<p>Paper on a promising Alzheimer\u2019s immunotherapy: engineered asymmetric anti-amyloid-\u03b2 antibody with a transferrin receptor binding domain for crossing the blood-brain-barrier and a mutation which mitigates harmful side effects seen in past versions of this type of treatment. #immunotherapy #alzheimers<\/p>\n<hr>\n<p>Amyloid-related imaging abnormalities (ARIA), side effects of anti-amyloid drugs seen in magnetic resonance imaging of the brain, are a major safety concern in patients with Alzheimer\u2019s disease. We developed an antibody transport vehicle (ATV) targeting transferrin receptor (TfR) for brain delivery of anti-amyloid-\u03b2 protein (anti-A\u03b2) using asymmetrical Fc mutations (ATV<sup>cisLALA<\/sup>) that mitigates TfR-related liabilities and retains effector function when bound to A\u03b2. Administration of ATV<sup>cisLALA<\/sup>:A\u03b2 in mice exhibited broad brain distribution and enhanced parenchymal plaque target engagement. This biodistribution reduced ARIA-like lesions and vascular inflammation. Taken together, ATV<sup>cisLALA<\/sup> has the potential to improve the next generation of A\u03b2 immunotherapy through enhanced biodistribution mediated by transport across the blood-brain barrier.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Paper on a promising Alzheimer\u2019s immunotherapy: engineered asymmetric anti-amyloid-\u03b2 antibody with a transferrin receptor binding domain for crossing the blood-brain-barrier and a mutation which mitigates harmful side effects seen in past versions of this type of treatment. #immunotherapy #alzheimers Amyloid-related imaging abnormalities (ARIA), side effects of anti-amyloid drugs seen in magnetic resonance imaging of the [\u2026]<\/p>\n","protected":false},"author":636,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,6],"tags":[],"class_list":["post-221216","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-robotics-ai"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/221216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/636"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=221216"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/221216\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=221216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=221216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=221216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}